The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update

Expert Opinion on Investigational Drugs
Rita KhouryGeorge T Grossberg

Abstract

Despite recent advances in Alzheimer's disease (AD) research, no breakthrough treatments have been discovered. Cholinesterase inhibitors and the NMDA-receptor antagonist memantine are currently the two approved symptomatic treatments for AD. 5-HT6 receptor antagonism has recently emerged as a promising treatment strategy to improve cognition in AD, with a modest side-effect profile. 5-HT6 receptors, exclusively found in the central nervous system, modulate primarily GABA and glutamate levels, facilitating the secondary release of other neurotransmitters including dopamine, noradrenaline, and acetylcholine, all of which are compromised in AD. This review discusses findings of preclinical and phase I-III clinical trials conducted with three major 5-HT6 receptor antagonists: idalopirdine, intepirdine, and SUVN-502, in the field of AD. Despite early positive findings, larger phase-III trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors. Paradoxically, 5-HT6 receptor agonists have also been shown to have cognitive enhancing properties. Thus, a better understanding of the mechanism of action of the 5-HT6 receptor and its lig...Continue Reading

References

May 28, 1993·Biochemical and Biophysical Research Communications·M RuatJ C Schwartz
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L A DawsonP Li
Apr 20, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·K Rockwood
May 15, 2007·Dementia and Geriatric Cognitive Disorders·Bengt WinbladHans Jörg Möbius
Jul 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lee E SchechterChad E Beyer
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neil UptonDavid J Virley
Jan 27, 2010·The Mount Sinai Journal of Medicine, New York·Daniel P Perl
Sep 28, 2010·International Journal of Geriatric Psychiatry·Gareth Maher-EdwardsPauline Williams
Oct 30, 2010·Drug News & Perspectives·Ilya Bezprozvanny
Feb 19, 2011·International Review of Neurobiology·Lee A Dawson
Feb 22, 2011·Clinical Trials : Journal of the Society for Clinical Trials·Chengjie XiongJohn C Morris
Jul 5, 2011·Drugs & Aging·Laxeshkumar Patel, George T Grossberg
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Apr 24, 2013·Alzheimer's Research & Therapy·María Javier Ramírez
Feb 7, 2014·Reviews in the Neurosciences·Agnieszka Nikiforuk
Oct 10, 2014·Lancet Neurology·Lon S Schneider
Dec 31, 2014·The International Journal of Neuropsychopharmacology·Shinji MatsunagaNakao Iwata
Jun 6, 2015·Current Pharmaceutical Design·Natasja M W J de Bruin, Chris G Kruse
Jun 23, 2015·Journal of Medicinal Chemistry·Delphine KarilaChristophe Rochais
Mar 4, 2017·Expert Opinion on Emerging Drugs·Amanda CalhounGeorge T Grossberg
May 28, 2017·Journal of Alzheimer's Disease : JAD·Alexandre V IvachtchenkoAndrey Ivashchenko
Oct 27, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jeffrey CummingsKate Zhong
Nov 9, 2017·Drugs & Aging·Rita KhouryGeorge T Grossberg
Jan 11, 2018·JAMA : the Journal of the American Medical Association·David A Bennett
May 7, 2015·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Gareth Maher-EdwardsMichael Gold

❮ Previous
Next ❯

Citations

Mar 5, 2019·Current Alzheimer Research·Firas H BazzariHanan S El-Abhar
Jan 8, 2020·Journal of Biomedical Science·Li-Kai HuangChaur-Jong Hu
Apr 25, 2020·EMBO Molecular Medicine·Coralie BerthouxCarine Bécamel
May 31, 2019·Proceedings of the National Academy of Sciences of the United States of America·Jason Y JiangAldebaran M Hofer
Mar 4, 2020·International Journal of Molecular Sciences·Julien Bacqué-CazenavePhilippe De Deurwaerdère
Jun 4, 2019·Frontiers in Pharmacology·Maria Grazia Morgese, Luigia Trabace
Aug 9, 2020·Frontiers in Neuroscience·Georg A Petroianu, Dietrich E Lorke
Dec 19, 2018·International Psychogeriatrics·Shinji MatsunagaHajime Takechi
Oct 16, 2019·Expert Opinion on Investigational Drugs·Garam LeeMarwan N Sabbagh
Mar 4, 2020·CNS & Neurological Disorders Drug Targets·Anamaria Jurcau, Aurel Simion
Feb 19, 2019·Journal of Alzheimer's Disease : JAD·John Wesson Ashford
Nov 22, 2020·Pharmacology, Biochemistry, and Behavior·Dionisio A AmodeoBryce C Ryan
Jan 21, 2020·Neuropharmacology·Philippe De DeurwaerdèreGiuseppe Di Giovanni
Jan 15, 2021·Molecular Neurodegeneration·Jeffrey Cummings
Feb 7, 2021·Brain Research·Brandon L OliverDionisio A Amodeo
Dec 4, 2020·Acta Pharmacologica Sinica·Feng ZhangWei-Dong Le
Mar 13, 2021·Ageing Research Reviews·Milan StoiljkovicMihály Hajós
May 8, 2021·Aging Cell·Zehui SunYan Zhang
Jun 8, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Frederick M LangJeffrey L Cummings
Jul 27, 2021·Bioorganic & Medicinal Chemistry Letters·Katarzyna Kucwaj-BryszJadwiga Handzlik
Jun 12, 2020·Neuropharmacology·Trevor Sharp, Nicholas M Barnes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Related Papers

Expert Opinion on Investigational Drugs
Daniela Galimberti, Elio Scarpini
Nature Clinical Practice. Neurology
Peter V Rabins, Constantine G Lyketsos
Neurología : publicación oficial de la Sociedad Española de Neurología
José L Molinuevo
© 2022 Meta ULC. All rights reserved